Medpace Beats Q2 Revenue Estimates
Medpace (NASDAQ:MEDP), a clinical contract research organization that manages drug development for pharmaceutical and biotech clients, reported its second quarter 2025 earnings on July 17, 2025. The company delivered GAAP results that topped both earnings and revenue forecasts, with GAAP revenue of $603.3 million versus the estimated $538.8 million and GAAP earnings per share (EPS) of $3.10 versus the expected $2.98. The period’s robust GAAP figures outpaced analyst estimates. Overall, the quarter featured both expansion in top-line results and continued operational progress, prompting management to raise forecasts for the remainder of FY2025.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Medpace is a clinical contract research organization, or CRO, specializing in running clinical trials to help pharmaceutical and biotech firms bring new drugs and treatments to market. Its work covers every phase of the clinical development cycle, providing a full suite of services like trial management, regulatory consulting, and data analysis. The company is known for its broad therapeutic expertise—especially in oncology, cardiology, metabolic disease, and infectious diseases—and for partnering closely with small and mid-sized drug development enterprises.
Source Fool.com
